HRV Global Life Sciences and Haleos Labs have formed a multi-year strategic partnership focused on accelerating the development and GMP manufacturing of high-value orphan-drug and niche-therapeutic active pharmaceutical ingredients (APIs). This alliance aims to serve regulated and semi-regulated markets, targeting rare diseases and complex conditions.
Strategic Alliance for High-Value APIs
HRV Global Life Sciences (HRV Pharma) and Haleos Labs have entered a significant collaboration to bolster the production of specialized pharmaceutical ingredients. The multi-year pact will focus on orphan-drug and niche-therapeutic active pharmaceutical ingredients (APIs), catering to stringent global regulatory standards. This partnership strategically positions both entities to address the growing demand for treatments targeting rare diseases and complex medical conditions.
End-to-End Development and Manufacturing
The alliance integrates Haleos Labs' established WHO-GMP-aligned systems and expertise in specialty API production with HRV Pharma's global market access and regulatory execution capabilities. The collaboration will encompass the entire value chain, from route scouting and process intensification to scale-up, validation, and commercial manufacturing. Both companies anticipate introducing an annual pipeline of five to seven new molecules, focusing on therapeutic areas such as ultra-rare conditions, central nervous system disorders, and metabolic diseases.
Global Regulatory Strategy
A key component of this partnership involves a joint, integrated regulatory strategy. This includes filing Drug Master Files (DMFs) across major global markets like the US, EU, Latin America, MENA, and APAC. The filings will be supported by comprehensive CMC (Chemistry, Manufacturing, and Controls) documentation, stability studies, validation programs, and essential technical data. HRV Pharma, known for its asset-light model, plans to leverage its digital platform and extensive commercial reach, integrating it with Haleos Labs' extensive chemistry expertise and manufacturing legacy.
Driving Future Growth
Hari Kiran Chereddi, MD and CEO of HRV Pharma, emphasized that the partnership is crucial for building a next-generation virtual API ecosystem, enabling global scale for specialized APIs. Praveen Talluri, Executive Director of Haleos Labs, highlighted the collaboration's role in advancing the company's entry into complex, high-value APIs for underserved patient populations. The initial phase of the collaboration has already led to the filing of multiple US DMFs, with additional orphan and niche programs slated for development annually.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
